109 related articles for article (PubMed ID: 32569015)
1. Effects of Dual Purinoceptor-dependent Approach on Release of Vascular Endothelial Growth Factor From Human Microvascular Endothelial Cell (HMEC-1) and Endothelial Cell Condition.
Gdula AM; Swiatkowska M
J Cardiovasc Pharmacol; 2020 Sep; 76(3):349-359. PubMed ID: 32569015
[TBL] [Abstract][Full Text] [Related]
2. A2
Gdula AM; Swiatkowska M
Microvasc Res; 2021 Nov; 138():104218. PubMed ID: 34182003
[TBL] [Abstract][Full Text] [Related]
3. Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y
Wolska N; Boncler M; Polak D; Wzorek J; Przygodzki T; Gapinska M; Watala C; Rozalski M
Molecules; 2019 Dec; 25(1):. PubMed ID: 31905703
[TBL] [Abstract][Full Text] [Related]
4. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
[TBL] [Abstract][Full Text] [Related]
5. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
6. Effect of ticagrelor on endothelial calcium signalling and barrier function.
Gündüz D; Tanislav C; Schlüter KD; Schulz R; Hamm C; Aslam M
Thromb Haemost; 2017 Jan; 117(2):371-381. PubMed ID: 27904901
[TBL] [Abstract][Full Text] [Related]
7. The role of purinergic P2Y
Korybalska K; Rutkowski R; Luczak J; Czepulis N; Karpinski K; Witowski J
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30415240
[TBL] [Abstract][Full Text] [Related]
8. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
9. Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.
Reiner MF; Akhmedov A; Stivala S; Keller S; Gaul DS; Bonetti NR; Savarese G; Glanzmann M; Zhu C; Ruf W; Yang Z; Matter CM; Lüscher TF; Camici GG; Beer JH
Cardiovasc Res; 2017 Jan; 113(1):61-69. PubMed ID: 28028070
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice.
Ganbaatar B; Fukuda D; Salim HM; Nishimoto S; Tanaka K; Higashikuni Y; Hirata Y; Yagi S; Soeki T; Sata M
Atherosclerosis; 2018 Aug; 275():124-132. PubMed ID: 29902700
[TBL] [Abstract][Full Text] [Related]
11. Differential mechanisms of adenosine- and ATPγS-induced microvascular endothelial barrier strengthening.
Bátori R; Kumar S; Bordán Z; Cherian-Shaw M; Kovács-Kása A; MacDonald JA; Fulton DJR; Erdődi F; Verin AD
J Cell Physiol; 2019 May; 234(5):5863-5879. PubMed ID: 29271489
[TBL] [Abstract][Full Text] [Related]
12. Pleiotropic effects of platelet P2Y12 receptor inhibitors: fact or fiction?
Moulias A; Xanthopoulou I; Alexopoulos D
Curr Pharm Des; 2014; 20(28):4597-604. PubMed ID: 24730531
[TBL] [Abstract][Full Text] [Related]
13. Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists.
Tang J; Li MP; Zhou HH; Chen XP
Curr Vasc Pharmacol; 2015; 13(5):566-77. PubMed ID: 25440595
[TBL] [Abstract][Full Text] [Related]
14. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.
Yanachkov IB; Chang H; Yanachkova MI; Dix EJ; Berny-Lang MA; Gremmel T; Michelson AD; Wright GE; Frelinger AL
Eur J Med Chem; 2016 Jan; 107():204-18. PubMed ID: 26588064
[TBL] [Abstract][Full Text] [Related]
15. Platelet phenotype changes associated with breast cancer and its treatment.
Holmes CE; Levis JE; Schneider DJ; Bambace NM; Sharma D; Lal I; Wood ME; Muss HB
Platelets; 2016 Nov; 27(7):703-711. PubMed ID: 27135253
[TBL] [Abstract][Full Text] [Related]
16. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
17. Adenosine inhibits neutrophil vascular endothelial growth factor release and transendothelial migration via A2B receptor activation.
Wakai A; Wang JH; Winter DC; Street JT; O'Sullivan RG; Redmond HP
Shock; 2001 Apr; 15(4):297-301. PubMed ID: 11303729
[TBL] [Abstract][Full Text] [Related]
18. G-protein-coupled receptors signaling pathways in new antiplatelet drug development.
Gurbel PA; Kuliopulos A; Tantry US
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):500-12. PubMed ID: 25633316
[TBL] [Abstract][Full Text] [Related]
19. Blunted coronary vasodilator response to uridine adenosine tetraphosphate in post-infarct remodeled myocardium is due to reduced P1 receptor activation.
Zhou Z; de Wijs-Meijler D; Lankhuizen I; Jankowski J; Jankowski V; Jan Danser AH; Duncker DJ; Merkus D
Pharmacol Res; 2013 Nov; 77():22-9. PubMed ID: 23994209
[TBL] [Abstract][Full Text] [Related]
20. G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.
Jacobson KA; Balasubramanian R; Deflorian F; Gao ZG
Purinergic Signal; 2012 Sep; 8(3):419-36. PubMed ID: 22371149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
